LAUSR

Myocardial infarction (MI) remains a leading global cause of mortality and is commonly treated with Captopril, Spironolactone, and Bisoprolol. Emerging therapies, such as the secretome derived from cardiosphere-derived cells (S-CDCs), have shown potential in reducing MI scar size. This study aims to evaluate the potential therapeutic implications of S-CDCs in MI treatment, particularly in relation to the aforementioned standard drugs. CDCs (n = 4) were isolated from cardiac explants of Large White pigs and cultured in DMEM with 1% ITS and antibiotics for four days. The conditioned medium was centrifuged and ultrafiltered (3 kDa) to obtain the S-CDCs. The content of S-CDCs, including miRNAs and genes, was analysed using transcriptomic and qPCR techniques. Bioinformatics tools were used to establish the interaction network (IN) of Captopril, Bisoprolol, and Spironolactone with their target genes through the String app within Cytoscape. miRTargetLink 2.0 was used to predict miRNA-gene interactions, and FunRich analysed the gene network. Finally, the content of S-CDCs was compared with previously identified miRNAs and genes, and an interaction network was generated using Cytoscape. Our findings show that S-CDCs contain six miRNAs that interact with target genes of Captopril and Spironolactone. Additionally, S-CDCs harbor genes that interact with those affected by the drugs, with a predominant influence from Spironolactone. S-CDCs may mimic the effects of Captopril and Spironolactone, potentially simplifying MI treatment. However, further studies are necessary to validate these findings.